Joel Batten
Jacksonville,FL
Summary
Sales and marketing leader driving growth across therapeutic areas. Proven track record of successful product launches and achieving over 100% growth in the first year. Expertise in go-to-market strategies and building high-performing teams to enhance commercial outcomes.
Overview
20
20
years of professional experience
Work History
Vice President, Sales & Marketing – Afrezza (Pediatric & Adult) And Furoscix Nephrology
MannKind Corporation
Remote / Westlake Village, CA
08.2025 - Current
- Lead U.S. sales and marketing across the Afrezza Diabetes franchise (Pediatric primary; Adult support), accountable for growth, execution, and portfolio performance
- Led two successful launches in 2026 in Endocrinology and Nephrology
- P&L ownership and owner of strategy for Sales, Marketing, Market Access and Commercial Operations
- Achieved over 100% for both lines of business in first year and ahead of goal for newly added Furoscix brand in 2026
- Report to President, Endocrine Business Unit; align Pediatric and Adult strategies to maximize portfolio performance.
- Built and scaled the Pediatric commercial organization, including national KAM leadership across East/West
- Built Pediatric launch team in 4 months inclusive of KAM team, Market Access support group and refined targeting and forecast
- Added newly acquired Furoscix brand into the field team inclusive of strategy, alignment, targeting and goal setting
- Built the integrated go-to-market plan (positioning, field execution, analytics, training, incentives) to improve adoption and target KPIs
- Partner with Medical, Market Access, Patient Services, and Analytics to accelerate execution
Chief Commercial Officer
42 Bio
Gainesville, FL
10.2023 - 08.2025
- Served as CCO for a private parent company managing Ferro Bio and Genix startups.
- Repositioned Genix commercially, driving 500% profitability growth.
- Led commercial strategy to expand CD34+ offerings across R&D, cord blood, and bone marrow processing
- Established competitive differentiation through data generation and evidence-based positioning.
- Expanded potential opportunities by identifying Bone Marrow processors as a potential new customer base
- Concentrated efforts on identifying and engaging clinical development sites and large cord blood processors.
- Expanding FerroBio applications allows for higher margin areas to focus to grow revenue faster than originally expected
- Aligned the GTM strategy to better fit the long term goals
Executive Vice President
Veru Pharma
Miami, FL
05.2022 - 10.2023
- As the first commercial employee, built franchise for new acute respiratory distress syndrome (ARDS) pharmaceutical from scratch with full accountability for Infectious Disease business with an anticipated year-one P&L of $1B.
- Operated as CEO of the commercial business unit
- Orchestrated development and implementation of commercial and medical infrastructure, including establishing market access strategy, sales structure, and commercial operations to lay groundwork for product launch in only five months.
- Developed, trained, and managed team, cultivating a culture of integrity, collaboration, communication, and passion to enhance team cohesion
- Regularly presented to the Board as the Head of the Commerical Business Unit
- Aligned initiatives with overarching strategy and devised performance management framework with detailed metrics and cross-functional checks to ensure accountability.
- Closely monitored emerging industry trends to shape and evolve strategy accordingly.
- Guided team through downsizing after unfavorable FDA decision, maintaining engagement and morale while ensuring productivity.
Infectious Disease Franchise Head and Executive Business Director, Synagis
Sobi North America (Acquired AstraZeneca/MedImmune)
Boston, MA
04.2006 - 05.2022
- Promoted to Executive Business Director in 9/18 and again to VP/Franchise Head 10/20. Oversaw full P&L, shaped overarching franchise strategy in alignment with business goals, and led 161-member team across the US and Puerto Rico through effective execution and delivery.
- Consistently exceeded national gross revenue forecasts for mature monoclonal antibody brand, growing from $560M in ’19 to greater than $600M annually in ’22.
- P&L ownership and owner of strategy for Sales, Marketing, Market Access and Commercial Operations.
- Headed development and implementation of brand strategy and cross-channel marketing campaigns to accelerate sales, market access, distribution, and patient access service.
- Transformed distribution model from FLW to Specialty distribution, enhancing profit margins and optimizing business operations.
- Led continuous improvement efforts and streamlined operational processes, achieving significant cost savings and increasing overall efficiency.
- Influenced business strategy by collaborating with global leadership, presenting regular reports, analyzing market research, and evaluating internal metrics.
- Established centralized decision-making system, fostering innovation and enhancing cross-functional alignment.
- Motivated team and created incentive program to recognize and reward success.
Commercial Business Director, Infectious Disease
Sobi North America (Acquired AstraZeneca/MedImmune)
Boston, MA
12.2016 - 09.2019
- Formulated innovative sales strategies and surpassed goals for three consecutive years, expanding Synagis market for Sobi and biologics market for AstraZeneca/MedImmune.
- Delivered $350M in sales revenue annually and won two Circle of Excellence Awards (’17 and ’19).
- Implemented nationwide external engagement strategy, enhancing brand visibility for respiratory biologics products.
- Led transition from AstraZeneca/MedImmune to Sobi post-acquisition, managing team of 10 including six Regional Sales Directors and four Institutional Directors across Western Region.
- Built high-performing team by hiring top talent, establishing clear expectations and goals, and mentoring on sales techniques to support career development.
- Enhanced data management and sales operations with introduction of critical tools, strategies, and best practices.
Public Health Director
Sobi North America (Acquired AstraZeneca/MedImmune)
Boston, MA
06.2015 - 12.2016
- Led nine-member team of Public Health and CDC Managers influencing Public Health policy across the US market.
- Generated additional revenue for AstraZeneca by developing national CDC strategy and selling complete allocation of federal vaccine doses.
- Increased Integrated Health Systems penetration by partnering with market access team to pioneer new cross-functional strategy to secure contracts and expand sales.
- Built Public Health Oncology program by setting up new system to strengthen Public Health programs around cancer.
- Facilitated cross-functional workshops on lung cancer biomarkers and screening to enhance knowledge sharing and collaboration.
- Received Circle of Excellence award in 2015 for outstanding contributions to public health.
Regional Director, State Government Affairs
Sobi North America (Acquired AstraZeneca/MedImmune)
Boston, MA
03.2014 - 06.2015
- Instrumental in influencing legislation and policy across all therapeutic areas by leading internal and external lobbyists, ensuring consistent messaging, strategy, and regulatory compliance.
- Cultivated relationships with legislators and staff in 22 states and Puerto Rico, managing engagements with BIO and PhRMA state chapters to advance policy objectives.
- Integrated two teams into cohesive government affairs organization, enhancing collaboration and focus on shared goals for therapeutic coverage.
- Developed state government strategy for cardiovascular and respiratory therapeutic areas, aligning advocacy efforts with legislative priorities.
Government Affairs Manager
Sobi North America (Acquired AstraZeneca/MedImmune)
Boston, MA
04.2009 - 03.2014
- Cultivated relationships and partnerships to guide legislative policy development and advocacy in Georgia, Florida, Alabama, and Puerto Rico.
- Facilitated physicians and legislators' influence on Medicaid’s pediatric policies through formation of advisory panel.
- Increased access for premature infants in Florida by streamlining prior authorization process and advocating for mandatory Medicaid coverage.
- Launched school health programs in all three states; obtained budget allocation to sustain program in Georgia.
- Advanced to Area Business Manager after serving as Clinical Marketing Manager.
District Manager
Sobi North America (Acquired AstraZeneca/MedImmune)
Boston, MA
07.2007 - 04.2009
- Achieved 1st in nation for vaccine growth and 2nd for Synagis growth, contributing to overall market expansion.
- Earned Circle of Excellence recognition and promoted to Market Access within 1 year for exceptional performance.
- Led team of 10 reps to promote Synagis and Flumist across Florida, driving regional sales growth.
Clinical Marketing Manager
Sobi North America (Acquired AstraZeneca/MedImmune)
Boston, MA
04.2006 - 07.2007
- Surpassed sales goals for both products, leading to promotion to manager within first year.
- Developed comprehensive marketing strategies aligned with company goals and market trends.
- Collaborated with cross-functional teams to launch new product campaigns successfully.
- Analyzed market data to identify opportunities for brand growth and customer engagement.
- Promoted Synagis and Flumist as hospital-based sales representative, increasing product awareness among healthcare providers.
Education
Bachelor of Arts - Public Relations
University of North Florida
Jacksonville, FLSkills
- Go-to-Market Strategy
- US Sales Leadership
- Franchise / P&L Leadership
- Market Access & Patient Services
- Brand Strategy & Positioning
- Commercial Analytics & KPIs
- Commercial Infrastructure Build-Out
- Strategic Partnerships
- Cross-Functional Leadership
- Talent Development & Team Building
- KOL / External Stakeholder Engagement
- Training
Therapeutic Areas
- Endocrinology (Diabetes)
- Infectious Disease
- Nephrology
- Vaccines
- Oncology/Hematology
- Cardiology
- Rheumatology
- Immunology
- Respiratory (Asthma, Allergies, COPD)
Timeline
Vice President, Sales & Marketing – Afrezza (Pediatric & Adult) And Furoscix Nephrology
MannKind Corporation
08.2025 - Current
Chief Commercial Officer
42 Bio
10.2023 - 08.2025
Executive Vice President
Veru Pharma
05.2022 - 10.2023
Commercial Business Director, Infectious Disease
Sobi North America (Acquired AstraZeneca/MedImmune)
12.2016 - 09.2019
Public Health Director
Sobi North America (Acquired AstraZeneca/MedImmune)
06.2015 - 12.2016
Regional Director, State Government Affairs
Sobi North America (Acquired AstraZeneca/MedImmune)
03.2014 - 06.2015
Government Affairs Manager
Sobi North America (Acquired AstraZeneca/MedImmune)
04.2009 - 03.2014
District Manager
Sobi North America (Acquired AstraZeneca/MedImmune)
07.2007 - 04.2009
Infectious Disease Franchise Head and Executive Business Director, Synagis
Sobi North America (Acquired AstraZeneca/MedImmune)
04.2006 - 05.2022
Clinical Marketing Manager
Sobi North America (Acquired AstraZeneca/MedImmune)
04.2006 - 07.2007
Bachelor of Arts - Public Relations
University of North Florida